Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

about

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

Item

http://www.wikidata.org/entity/Q49383683

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@en

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@nl

type

Item

label

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@en

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@nl

prefLabel

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@en

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@nl

P1476

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

@en

P2093

Ajit Suri

http://www.w3.org/2001/XMLSchema#string

David M Hyman

http://www.w3.org/2001/XMLSchema#string

Geoffrey Kim

http://www.w3.org/2001/XMLSchema#string

Jin Y Jin

http://www.w3.org/2001/XMLSchema#string

Yan Ji

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.

Rational combinations of immunotherapeutics that target discrete pathways.

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Clinical development success rates for investigational drugs.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Dose escalation methods in phase I cancer clinical trials.

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

P31

scholarly article

review article

P356

10.1111/CTS.12540

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29392871

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

6039198

http://www.w3.org/2001/XMLSchema#string